Abstract | BACKGROUND/AIMS: METHODOLOGY: We established an open-label, randomized trial to assess the effect of somatostatin on the patients with primary gastric cancer and total gastrectomy. All the 60 patients were randomly divided into somatostatin pretreatment and placebo groups and we used ELISA, real-time PCR and immunohistochemistry analysis to identify the level of VEGFs. RESULTS: The results showed that the patients pretreated with somatostatin had a significant decrease in serum VEGF level, but not in the tissue mRNA level, and the decrease in serum VEGF was partially dependent on the synthesis and degradation of the protein but not the transcription of mRNA. We also found the tissue Flt-4 (VEGFR-3) protein decreased in somatostatin pretreatment group. CONCLUSIONS:
|
Authors | Bin Zhao, Peimin Yang, Jing Yang, Duan Cai |
Journal | Hepato-gastroenterology
(Hepatogastroenterology)
2011 Jul-Aug
Vol. 58
Issue 109
Pg. 1425-30
ISSN: 0172-6390 [Print] Greece |
PMID | 21937420
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Angiogenesis Inhibitors
- Vascular Endothelial Growth Factor A
- Somatostatin
- Receptors, Vascular Endothelial Growth Factor
- Vascular Endothelial Growth Factor Receptor-3
|
Topics |
- Angiogenesis Inhibitors
(pharmacology)
- Female
- Gene Expression Regulation, Neoplastic
(drug effects)
- Humans
- Male
- Middle Aged
- Receptors, Vascular Endothelial Growth Factor
(analysis, genetics)
- Somatostatin
(pharmacology)
- Stomach Neoplasms
(drug therapy, metabolism)
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors, blood, genetics)
- Vascular Endothelial Growth Factor Receptor-3
(antagonists & inhibitors)
|